Clinical Trials Logo

Dermatosis Papulosa Nigra clinical trials

View clinical trials related to Dermatosis Papulosa Nigra.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT06099080 Active, not recruiting - Clinical trials for Dermatosis Papulosa Nigra

A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Dermatosis Papulosa Nigra (DPN)

Start date: November 7, 2023
Phase: Phase 2
Study type: Interventional

An open-label trial to explore the safety and efficacy of SM-020 gel 1.0% in subjects with Dermatosis Papulosa Nigra (DPN). Approximately 10 subjects will be enrolled with DPNs to apply SM-020 gel 1.0%. Each subject must have a minimum of 5 eligible DPNTLs with a diameter ≥2mm but ≤5mm. A maximum of 10 DPNs per subject will be targeted for treatment. Subjects will apply the investigational product twice daily for 4 consecutive weeks. Subjects will be followed for 12 weeks post final application for a total of approximately 16 weeks of required participation in the study. A total of 5-10 eligible Dermatosis Papulosa Nigra Target Lesions (DPNTLs) will be treated per subject.